Engineered immune cells take aim at a rare Protein-Folding disease

NCT ID NCT07765524

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial is testing an experimental treatment called FKC289 for people with primary AL amyloidosis that has relapsed or not responded to standard care. FKC289 uses a patient's own immune cells, engineered to recognize and attack the abnormal plasma cells that produce the harmful protein deposits. The study aims to assess the safety of this therapy and determine the best dose, as well as to see how effective it is at reducing signs of the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
FKC289, a CAR-T cell therapy that targets BCMA and CD19 on plasma cells
What this could lead to
If successful, this could offer a new treatment option for people with AL amyloidosis that has returned or not responded to other therapies, potentially leading to remission.
What could go wrong
This is an early-stage trial with a small number of participants, so results may not be conclusive. CAR-T therapy carries risks like severe immune reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY LIGHT CHAIN (AL) AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, 250012, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, 610000, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510700, China

  • The Frist Affiliated Hospital of Guangxi Medical university

    Nanning, Guangxi, 530021, China

  • The Frist Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, 510600, China

  • The Second Affiliated Hospital Zhejiang University school of Medicine

    Hangzhou, Zhejiang, 310009, China

  • Tongji Mecial college of HUST

    Wuhan, Hubei, 430030, China

  • West China Hospital Sichuan Hospital

    Chengdu, Sichuan, 610000, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200032, China